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DIALYSIS - TRANSPLANTATION
Low efficiency of active immunization against diphtheria in
chronic hemodialysis patients
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Lübeck, Germany
Low efficiency of active immunization against diphtheria in chronic
hemodialysis patients. Recent epidemiological studies indicate a low
immunity to diphtheria in adults in industrialized countries. In the light of
the epidemic increase of diphtheria in Countries such as Russia and the
Ukraine, systematic vaccination against this disease is recommended. We
analyzed the immunity to diphtheria of 228 hemodialysis patients and the
efficiency of single versus triple vaccination against diphtheria. Antibodies
against diphtheria toxoid were determined by enzyme immunoassay in
sera of 228 adult hemodialysis patients. Fifty-four patients were triple
vaccinated against diphtheria and were followed for six months; 17
patients were single immunized and antitoxoid titers were determined 1
and 12 months later. The overall protection rate against diphtheria was
22% and equal in male and female patients. After triple immunization,
only 35% of the patients developed protective antibody concentration(> 0.1 IE/mI) six months after the third vaccination. A single vaccination
caused protective titres twelve months later in 41% of the patients. There
was no difference between responders and non-responders in the duration,
intensity or modality of hemodialysis treatment or the response to
previous vaccinations against hepatitis-B. We suggest to monitor antibod-
ies against diphtheria toxoid in vaccinated hemodialysis patients at risk for
diphtheria since protective titers are often not attained by the standard
vaccination protocol.
Recent epidemiologieal studies indicate that less than 50% of
the general population (such as in Western Europe) are suffi-
ciently protected against diphtheria as judged by anti-diphtheria
toxoid titers [1, 2]. This is important since in Russia, the Ukraine
and other states of the former USSR (such as Azerbeijan, Belarus,
Kazahstan) the incidence of diphtheria has rapidly increased
between 1990 and 1995 [3, 4]. Accordingly, the vast majority of
cases (99%) reported in Europe in 1993 were diagnosed in the
former USSR [3], where it affects predominantly adults. Trans-
mission to other countries (Finland, Poland) has occurred [5, 6]
and offers the potential for a recurrence of outbreaks of this
disease in insufficiently immunized communities [7]. Smaller
outbreakes of diphtheria have been reported from different areas
in the United States [8—10] and different European States [11],
such as Sweden [12] within the last decades. Systematic active
immunizations of children and adults against diphtheria are
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recommended worldwide in comparable protocols [13—16]. As a
consequence, at twelve months of age about 78% of children have
been immunized against diphtheria globally (Western Pacific
93%, Europe 85%, Africa 56%) [17].
In chronic hemodialysis patients, immunization against viral
[18—20] and bacterial [21—23] infections is less successful than in
healthy subjects. Whether or not the protocol for vaccination
against diphtheria recommended for healthy adults is effective in
hemodialysis patients has not yet been studied. In order to test
whether immunization with diphtheria toxoid results in protective
titers, we performed a serological survey for immunity to diph-
theria and for the efficacy of active triple or single immunization
in chronic hemodialysis patients.
METHODS
Patients and serum sampling
A total of 228 chronic hemodialysis patients (102 female, 126
male) from five dialysis centers in northern Germany (Schleswig-
Holstein and Niedersachsen) were included into our study, which
was approved by the local ethics committee. The clinical data of
these patients are summarized in Table 1. Blood samples prior to
and after vaccination were drawn during routine monthly controls
before hemodialysis. Serum was fractionated, stored at —40°C and
tested only once after thawing.
Detection of diphtheria antitoxoid antibodies
The concentration of diphtheria antitoxoid antibodies was
determined by enzyme immunoassay (EIA; Immuno, Heidelberg,
Germany) using diphtheria-toxoid-linked peroxidase to detect
serum antibodies bound to diphtheria toxoid on the microtiter
plate [1]. Antitoxin was calibrated by the current WHO standard
for diphtheria antitoxin. Calibration was checked by the reference
method (according to the recommendation of the European
Pharmacopoeia) using intracutaneous injection in guinea pigs
(Schick-test) and expressed in lU/mi. The lower limit of detection
was 0.01 lU/mi and the diagnostic specificity was 100%. Each
serum titer was determined in duplicate. The antitoxin concen-
trations obtained were classified according to the following cate-
gories of protection: no or inadequate protection (< 0.1 lU/mi)
and protection ( 0.1 lU/mi). Effective seroconversion was de-
fined as an antibody concentration  0.1 lU/mi three or six
months after vaccination.
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Table 1. Clinical characteristics and their relation to immune status
against diphtheria of 228 patients included into the study 70
Total < 0.1 U/ml  0.1 U/mI
All patients % 228 176 (77.2%) 52 (22.8%)
Female % 103 83 (80.5%) 20 (19.5%)
Male % 125 93 (74.4%) 32 (25.6%)
Year of birth1 1935.5 15.4 1936.3 15.4 1932.6 13.7e
Duration of FID,d 42.4 41.5 43.5 42.0 39.9 37.7
HD hours/week 12.15 2.5 12.32 2.49 11.5 2.4c
Hemodiafiltration % 74 (32.5) 55 (74) 19 (26)C
Hemodialysis % 154 (67.5) 121 (78.6) 33 (21.4)e
Time before/after triple vaccination
Vaccination schedule
A triple immunization at zero, one and six months with
diphtheria toxoid ('d', 4 IE!injection; Chiron-Behring, Marburg,
Germany; charge 26071 and 27011) or a combination of tetanus!
diphtheria toxoid ('Td'; 40 IE tetanus toxoid, 4 IE diphtheria
toxoid, Chiron-Behring, charge 21021A) was recommended to all
patients who (a) did not possess any vaccination documents or (b)
had not been immunized against diphtheria and (c) did not
present with contraindications for vaccination [14, 15]. This
protocol followed the recommended immunization schedule for
persons seven years of age or older not immunized in infancy [171.
According to contraindications detailed by the manufacterer,
patients with recent or ongoing acute or chronic infectious
diseases or any history of allergy after vaccination or immunosup-
pressive therapy were excluded from the study. Patients with
severe neurologic disease were also excluded from immunization.
Recommendations for immunization were not made on the basis
of our serological findings prior to vaccination. All patients were
immunized after their dialysis treatment by i.m. injection (needle,
25 G) into the M. deltoideus of the contralateral arm of the
vascular dialysis access. Anticoagulation for hemodialysis therapy
was not altered for vaccination purposes. All patients were
interviewed for side effects after vaccination for up to two weeks
after the injection.
Statistics
Statistical analysis of serological results was performed by the
Sokal test [24]. Clinical data were analyzed by the Mann-Whitney
U-test [251. Differences were considered significant at P values
of < 0.05.
RESULTS
Immunity against diphtheria in hemodialysis patients
Only 52 of 228 patients (22.8%) without a documented history
of vaccination had anti-diphtheria titers  0.1 IU/ml, whereas
77.2% of all patients were not sufficiently immunized against this
disease. There was no significant correlation between age, sex or
the duration of hemodialysis therapy and the antibody concentra-
tions measured in these patients (Table 1). While 107 patients
agreed to any suggested vaccination protocol, 121 patients were
excluded because of contraindications including anticoagulation
(N = 4), cancer (N = 5), autoimmune disease (N = 5), terminal
disease with short life expectance (N = 17) or because they did
Fig. 1. Number of hemodialysis patients protected (,  0.1 lU/mi) or
unprotected (E, 0.1 lU/mI) by anti-diphtheria-toxoid antibodies before(A) and six months after (D) triple immunization against diphtheria
('Td-d.d, d-d-d'). B. One month after the first vaccination, and C prior to
the third vaccination.
not agree to the immunization protocol (N = 38). In addition,
patients from one particular dialysis center were not vaccinated
because these patients were included into another immunization
study (N = 52). Thus, 46.9% of all patients received a vaccination
against diphtheria.
Seroconversion rates after triple vaccination ('Td-d-d' or 'd-d-d')
Seventy-two hemodialysis patients were designated to the triple
vaccination protocol. Eleven of these patients were lost during the
vaccination or follow-up period due to death. Of the remaining 61,
seven of them had protective antibody concentrations before
vaccination and were therefore not included into the study.
Therefore, 54 patients (22 women, 32 men) with a negative history
of diphtheria vaccination and antibody concentrations < 0.1
lU/mi were immunized against diphtheria at 0, one and seven
months. Twelve patients received 'd-d-d' and 42 were immunized
by 'Td-d-d'.
One month after the first injection 27 of 54 patients (50%)
developed protective antitoxoid antibody concentrations above
0.1 lU/mi. Of 50 patients assessed six months after the second and
just prior to the third vaccination, 22 (44%) still retained antitox-
oid titers  0.1 lU/mi. Six months after the third injection, the
number of the patients considered to be well immunized dropped
to 35% (19 of 54; Fig. 1).
Of the 27 patients who were below protective levels both prior
to and four weeks after the first of three vaccinations (initial
non-response), only 3 (11.7%) were  0.1 IU!ml six months after
the third injection, and thus responded to the second and third
vaccinations. In contrast, 16 out of 27 patients (59%) who were
unprotected before the first injection but  0.1 lU/mI four weeks
later (initial response) still retained protective titers six months
after the third vaccination (P < 0.05 vs. initial non-response). We
did not detect any differences between responders and non-
responders to the triple vaccination protocol with respect to age,
sex, duration of hemodialysis treatment, the numbers of hours
spent on dialysis per week, blood hemoglobin levels, or white cell
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Table 2. Clinical data from 54 hemodialysis patients, who were
unprotected at baseline (< 0.1 lU/mi) and responded (0.1 lU/mi) or
did not respond (< 0.1 lU/mI) to triple vaccination against diphtheria
Responders(N = 19)"
Non-responders(N = 35)"
Age years, months" 59.6 14.9 58.1 14.7"
Female/male 7/12 15120h
Duration of HD months" 37.3 46.9 51.0 45.3"
HD hours/week" 12.4 1.4 11.9 2.4"
Blood hemoglobulin g/iiter"
White blood cells/nI"
9.85 1.61
7.53 1.5
10.0 1.7"
7.31 2.57"
Blood platelets/ni"
Hepatitis-B vaccination"
Erythropoietin lU/week""
Parathyroid hormone"
277 95
9/19 (5)
3700 2226
292 444
235 81h
17/35 (9)h
4051 3386h
292 350"
1,25-D3 treatment .rg/week" 0.87 0.97 1.46 1,1h
Phosphorus' 2.44 0.63 2.26 0.81"
Calcium5 2.43 0.35 2.41 0.25"
—
Evaluated six months after the last of three injections
Mean standard deviation
Hemodialysis/weekd Among 19 responders to diphtheria vaccination 9 (47%) responded to
previous hepatitis-B immunization; among 35 non-responders to diphthe-
ria vaccination 17 (48%) responded to hepatitis-B vaccine. The number of
patients in whom immune response to hepatitis-B could not be evaluated
is given in parenthesis.
Erythropoietin was given three times per week subcutaneously
pg/mi (normal range 15—55)
g mmol/liter
P > 0.05 versus responders (U-test: Sokal-test)
counts. In particular, no association between the vaccination
efficiency and the weekly applied erythropoietin treatment or the
response to vaccination against hepatitis B was observed (Table
2).
The underlying renal disease was also unrelated to the response
to diphtheria vaccination. The renal diagnosis (non-responders/
responders) were: unknown (11/7), diabetes mellitus type 1(3/1),
diabetes mellitus type 11(3/3), interstitial nephritis (3/2), various
forms of glomerulonephritis (4/4), adult polycystic disease (6/1) or
miscellaneous (4/4).
Seroconversion rates after single vaccination ('Td' or 'd')
Of 35 patients assigned for single immunization, three died
within in the follow up period and 15 were excluded because of
protective antibodies  0.1 IU/ml at baseline. The remaining 17
patients, being unprotected by an antibody concentration < 0.1
IU/ml and without a documented history of diphtheria vaccina-
tion, were immunized by a single injection of either 'Td' or 'd'. We
found that one month later 7 of 16 (44%) patients were  0.1
lU/mi (at 12 months, 7 of 17; 41%). Thus, the percentage of
protection in the single immunization group was not lower than in
the triple immunization protocol at the end of the control period
(P> 0.05).
Side effects
With more than 240 i.m. injections applied, only one patient
presented with severe swelling and pain in his left shoulder at the
site of inoculation of 'Td' two days before. This person had most
likely been vaccinated against tetanus within recent years, but did
not have vaccination certificates. In all other patients, no signifi-
cant side effects of the application of 'Td' or 'd' were observed.
Despite the maintenance of anticoagulation prior to i.m. injec-
tions we experienced no significant haematoma and no bleeding
complications.
DISCUSSION
The introduction and widespread use of active diphtheria
toxoid immunization in the 1940s was associated with a remark-
able decline of morbidity and mortality [141. In the United States
the incidence of diphtheria declined continuously from > 100/
100,000 in the 1920s to less than 0.01/100,000 in 1980 [8, 14, 26].
However, recent epidemiological surveys indicate a low overall
protection rate particularly in adults in different European states
[1, 2, 6, 16, 27]. The high proportion of susceptible individuals
emphasized recommendations to maintain diphtheria immunity
by triple inoculations in the absence of vaccination certificates,
followed by periodic revaccination in 10 year intervals [15, 161.
Primary vaccination is very effective in healthy individuals [28—
31], and when followed by booster immunizations prevents the
disease in the vast majority.
We tested the hypothesis that chronic hemodialysis patients
without a documented history of diphtheria immunization may be
successfully vaccinated against diphtheria by primary immuniza-
tion. The rationale for our study was the low serological response
of hemodialysis patients to vaccination against tetanus [22, 23],
hepatitis B [19, 201, influenza [181 and pneumococcus [211, and
the lack of data concerning the efficacy of diphtheria vaccination
in a chronic hemodialysis population. If, however, a vaccination is
suggested to patients the success rate of this preventive measure
should be assessable.
Our data demonstrate that only 22% of the hemodialysis
patients in northern Germany are protected against diphtheria by
antibody concentrations  0.1 lU/mi. This number is lower than
the age-matched average found in a recent serological survey in
the same geographic region [1]. In our study, protection against
diphtheria was not related to age, sex, duration or intensity of
hemodialysis treatment.
Following the recommendations for vaccination against diph-
theria in adults who had no documented history of vaccination
[15], we immunized 54 of 228 hemodialysis patients by triple
injections and followed them for a total of 13 months. The low
initial response rate of 44% is in line with the low response rate of
50 to 60% after hepatitis-B vaccination [19]. Given the overall
protection rate of 35% at six months after the diphtheria vacci-
nation, this regime cannot be judged to be effective for the
majority of hemodialysis patients. In this protocol the response to
the first vaccination was very predictive of the final efficacy of the
procedure. The decline after an initial response to diphtheria
vaccination is comparable to that found with pneumococcal
vaccination at one year in hemodialysis patients [21]. The alter-
native single immunization protocol applied in patients who
refused the second and third injection was at least as effective as
the triple vaccination protocol, demonstrating protection in 42%
of the patients 12 months later.
We applied the official recommendations for immunization [151
to a special subgroup of patients with chronic renal diseases. A
control group of age-matched healthy adults or patients with mild
renal insufficiency was not included in this study, since the
efficiency of diphtheria vaccination in healthy adults has been well
documented [28, 30, 311.
While the efficiency of tetanus immunization in hemodialysis
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patients is correlated to the immune response to hepatitis B
vaccination [22], we were not able to demonstrate such correlation
in our study. Although erythopoietin treatment is associated with
higher mean titers and increased response rates after hepatitis-B
vaccination in hemodialysis patients [32, 33], we did not detect
differences in diphtheria-toxoid responders and non-responders
with respect to the intensity of erythropoietin treatment. We were
not able to identify clinical clues (such as age, sex, underlying
renal disease, duration and intensity of renal replacement ther-
apy) that help to predict the serological outcome of diphtheria
vaccination in this population.
Our data provide further support for a severe immune dysregu-
lation present in chronic hemodialysis patients. The immune
deficiency and the lack of adequate response to vaccination in
chronic hemodialysis patients has been linked to a deficit in the
antigen presenting capacity of macrophages [34]. This deficit can
be attributed to a failure of antigen presenting cells to provide
appropriate costimulatory signals (such as B7) to T-lymphocytes
[351. In this context, the impaired monocyte function [36] de-
creased interleukin-2 levels [37], reduced phagocytosis and ele-
vated levels of immunosuppressive complement fragments [38, 39]
in hemodialysis patients may be of significance. Patients with
chronic renal diseases, therefore, have an increased risk for
infections. Vaccinations are an important tool in altering this risk,
but the impaired cell-mediated and humoral immune-response
limit their benefits.
Nephrologists should immunize their hemodialysis patients
against diphtheria (and tetanus) by the standard protocol over six
months, provided there is no information on former vaccinations
against the disease. Revaccination should be performed in those
who have been immunized at 10 year intervals. However, hemo-
dialysis patients who are immunized by the standard protocol may
still not be sufficiently protected against diphtheria as jugded by
the detection of specific antitoxoid antibodies. In countries where
immigration from epidemic areas is high and the general immu-
nity to diphtheria is low, the lack of individual protection against
diphtheria constitutes a serious threat to these patients. We
recommend regular controls of anti-diphtheria-toxoid antibodies
in hemodialysis patients who are at risk for diphtheria and have
been immunized against this disease. These controls should be
initiated not earlier than four weeks after the last immunization.
Whether or not non-responders to the recommended protocol
should be revaccinated is currently being studied.
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